Roivant Sciences (ROIV) Payables (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Payables came in at $18.0 million in Q1 2026, down 24.01% YoY from $23.7 million in Q1 2025, and up 35.41% on a QoQ basis from $13.3 million in Q4 2025.
Roivant Sciences (ROIV) Payables (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Payables data on file, last reported at $18.0 million in Q1 2026.
- Quarterly Payables fell 24.01% year-over-year to $18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (down 24.01% YoY) and the FY2026 annual result came in at $18.0 million, down 24.01% from the prior year.
- Payables improved to $18.0 million in Q1 2026, from $13.3 million in the prior quarter.
- In the past five years, Payables ranged from a high of $194.6 million in Q2 2022 to a low of $11.5 million in Q2 2025.
- A 5-year average of $38.7 million and a median of $27.7 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables jumped 1196.18% — and 2023, when it slumped 74.29%.
- Tracing ROIV's Payables over 5 years: stood at $48.0 million in 2022, then fell by 26.61% to $35.2 million in 2023, then tumbled by 32.69% to $23.7 million in 2024, then sank by 43.94% to $13.3 million in 2025, then surged by 35.41% to $18.0 million in 2026.
- The last three Payables figures came in at $18.0 million (Q1 2026), $13.3 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.08 Mn |
| Mar 31, 2026 | 18.00 Mn |
| Dec 31, 2025 | 13.29 Mn |
| Sep 30, 2025 | 15.06 Mn |
| Jun 30, 2025 | 11.55 Mn |
| Mar 31, 2025 | 23.69 Mn |
| Dec 31, 2024 | 23.71 Mn |
| Sep 30, 2024 | 25.13 Mn |
| Jun 30, 2024 | 27.74 Mn |
| Mar 31, 2024 | 14.03 Mn |
| Dec 31, 2023 | 35.23 Mn |
| Sep 30, 2023 | 44.12 Mn |
| Jun 30, 2023 | 50.04 Mn |
| Mar 31, 2023 | 37.83 Mn |
| Dec 31, 2022 | 48.00 Mn |
| Sep 30, 2022 | 41.36 Mn |
| Jun 30, 2022 | 194.61 Mn |
| Mar 31, 2022 | 34.58 Mn |
| Dec 31, 2021 | 24.36 Mn |
| Sep 30, 2021 | 77.16 Mn |